Trial Profile

A PolyPEPI-SCoV-2 vaccine clinical trial for COVID-2019 infections

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PolyPEPI-SCoV-2 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

19 Oct 2020 According to a PepTC Vaccines Limited media release, Pre-IND regulatory confirmations were obtained from FDA (US), MHRA (UK) and PEI (Germany).
22 Jun 2020 New trial record
15 Jun 2020 According to a Treos Bio media release, PepTC Vaccines expects to advance to human clinical studies for its investigational PolyPEPI-SCoV-2 vaccine by October 2020. It expects to have preliminary trial results in March 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com